2026 ISLH Webinar Series: March 2026
10/03/2026
On Thursday, March 26th 2026, at 12:00 AM ET (16:00 PM CET) the International Society for Laboratory Hematology will host a webinar in the 2026 e-Learning series: "VITT explained".
The webinar will be presented by Ted Warkentin Professor Emeritus, McMaster University, Hamilton, Ontario, Canada, Razan H. Zulkeflee Department of Hematology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, will be the Moderator.
Vaccine/virus-induced immune thrombocytopenia and thrombosis (VITT) is an ultrarare but extreme prothrombotic disorder that features autoantibodies that target platelet factor 4 (PF4). As with immune heparin-induced thrombocytopenia (HIT), pathogenic VITT antibodies activate platelets, neutrophils, and monocytes, producing marked hypercoagulability with greatly increased risk of venous and arterial thrombosis.
Very recently, the immunopathogenesis of VITT was solved: the surprising explanation is unprecedented in the immunology literature, and thus may provide a roadmap for explaining other rare disorders that feature distinct triggers.
This lecture will summarize current concepts regarding VITT, including the important message that clinicians and laboratorians need to be on the lookout for future cases of VITT secondary to viral triggers, even as the adenoviral-vector COVID-19 vaccines that first resulted in its identification in 2021 have been discontinued from the marketplace.
Learning Objectives:
-
Describe the history of VITT.
-
Describe laboratory features of VITT.
-
Describe the spectacular immunopathogenesis of VITT (Feb 12, 2026 NEJM publication).
We look forward to your participation in this event! There is no charge to participate in the live webinar.
Notizie collegate
